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CObjectives: Streptococcus pneumoniae causes significant morbidity and
mortality worldwide. Static pharmacoeconomic models have been
used to conduct pharmacoeconomic analyses of pediatric pneumococ-
cal conjugate vaccination programs. The objective of this study was to
develop a transmission dynamic model to evaluate the cost-effective-
ness of a 13-valent pneumococcal conjugate vaccine (PCV13) in
Taiwan. Methods: An age-structured transmission dynamic model
as populated with parameters from the Taiwanese National Health
nsurance Research Database and publicly available sources to evalu-
te the clinical and economic impact of PCV13. Sensitivity analyses
ere performed to explore model uncertainties. Results: In the base-
ase analysis, four-dose scheduled universal infant PCV13 vaccination
ill prevent 5112 cases of invasive pneumococcal diseases, 535,607
ases of all-cause hospitalized pneumonia, 726,986 cases of acute otitis
edia, and 420 deaths over a 10-year time horizon since 2009. Theour-dose vaccination program is estimated to yield an incremental O
e no
s and
al So
doi:10.1016/j.jval.2011.11.013ost-effectiveness ratioof US$38,045 and US$18,299 from payer and so-
ietal perspectives. One-way sensitivity analyses indicated that the
ncremental cost-effectiveness ratio is most sensitive to vaccine price.
he 95% confidence interval of the incremental cost-effectiveness ratio
as US$10,186 to US$34,563 by multivariate probabilistic sensitivity
nalyses in the societal perspective. Conclusions: With a World
ealth Organization–recommended cost-effectiveness threshold, the
CV13 vaccination program would be cost-effective in Taiwan. To cir-
umvent the lack of long-term real data, a transmission dynamic
odel is informative to decision makers on evaluating the long-term
ost-effectiveness of PCV13.
eywords: cost-effectiveness, herd effect, Streptococcus pneumoniae,
ransmission dynamic model, 13-valent pneumococcal conjugate vac-
ine (PCV13).
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Infectious disease is one of the major causes of morbidity and
mortality among children younger than 5 years [1]. The World
Health Organization reported that five of the top seven diseases in
developing countries were caused by infectious pathogens [2].
Streptococcus pneumoniae (SP) causes invasive pneumococcal dis-
ases (IPDs; meningitis and bacteremia) and non-IPDs (pneumo-
ia and acute otitis media [AOM]). In Taiwan, pneumococcal dis-
ases constitute a considerable proportion of the overall disease
urden among high-risk groups: namely, children younger than 2
ears and those older than 65 years [3,4]. A recent study found that
80.7% of SP isolates from Taiwanese children younger than 14
ears were penicillin resistant. Despite the implementation of
tringent antibiotic-prescribing protocols, Taiwan has one of the
ighest rates of antibiotic-resistant SP in the world [5].
Seven-, 10-, and 13-valent pneumococcal conjugate vaccines
(PCV7, PCV10, and PCV13) have been introduced to prevent SP in-
fection in children. PCV7 is included as the routine national im-
Conflicts of interest: The authors have indicated that they hav
* Address correspondence to: Chang Chee Jen, Clinical Informatic
Wen-Hwa 1st Road, Kwei-Shan Taoyuan 333, Taiwan.
E-mail: cjchang@mail.cgu.edu.tw.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.munization schedule in many countries [6]. PCV13 was developed
owing to epidemiological changes of pneumococcal diseases.
Comparedwith PCV7, PCV13 targets six additional serotypes of the
same carrier protein (CRM197) [7].
Surveillance data indicated that mass vaccination protects
children fromacquiring pneumococcal diseases and reduces over-
all incidence [8-11]. This is known as the herd effect, a reduction in
disease transmission from the vaccinated to the unvaccinated
withwhich its inclusionwould increase the cost-effectiveness of a
vaccine [12,13]. Many pharmacoeconomic studies have utilized the
decision analytic orMarkovmodel [14] (collectively termed the static
model) to evaluate the cost-effectiveness of PCV7 [15-17]. A recent
cost-effectiveness analysis (CEA) of PCV7 in Hong Kong [18] incorpo-
rated theherd effect into themodel byusing observational data from
theUnited States [8]. One of themajor limitationswith staticmodels
is that the force of infection (FOI), defined as the per-capita rate of
infection, is assumed to be unaffected by a vaccination program [19].
Instead, a transmission dynamic model (TDM) treats FOI as depen-
dent on thenumber of infected persons over time [20].Much empha-
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S16 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 5 – S 1 9sis has been placed on the use of the TDM to evaluate the cost-effec-
tiveness of a vaccination program as more appropriate than the
static model because the TDM treats FOI as time dependent [21,22].
To our knowledge, there are only three studies that used the TDM to
explore the transmission dynamics of SP [23-25].
Methods
Transmission dynamic model
An age-stratified TDM was developed to simulate the clinical and
economic outcomes over 10 years. Age groups were chosen ac-
cording to demographic and epidemiological data to account for
various incidences of pneumococcal diseases. The model com-
prised seven major compartments: susceptible, S(t); vaccinated,
V(t); SP infection without vaccination, IV
C(t); SP infection with vac-
cination, IV(t); SP-induced death without vaccination, DV
C(t); SP-
induced deathwith vaccination,DV(t); and recovery frompneumo-
coccal diseases, R(t) (see Fig. 1 in Supplemental Materials found at
doi:10.1016/j.jval.2011.11.013). Each represented the number of in-
dividuals at a certain time point t. These compartments were fur-
ther divided into six age groups: i  1, 2, . . . ,6, i.e., 2, 3–4, 5–17,
18–49, 50–64, and65, where N represents the overall Taiwanese
population in 2009. Newbornswere assumed to be susceptible and
entered into S1(t) at the annual birth rate ì, with the current birth
cohortmoving into the next higher age group S2(t), and so on, until
he last age group, which was assigned an aging rate Ai, the recip-
rocal of the length of age group i. These aging rates were also
applied to other age-specific compartments. ˙ denoted the non-
P–inducedmortality rates for individuals of age group i in suscep-
ible and vaccinated compartments. Susceptible individuals of age
roup i were vaccinated with vaccine coverage and entered into
he vaccinated compartment, and vaccinated individuals became
usceptible again at vaccine-waning rate , which was the mean
ate at which vaccinated individuals lost their immunity (equiva-
ently, 1/ was the mean duration of vaccine-derived immunity).
usceptible individuals of age group i acquired one of the jth pneu-
ococcal diseases (j  1, 2, 3 for IPD, all-cause hospitalized pneu-
onia, and all-cause AOM) with FOI, ij(t), and entered into one of
he three infectious compartments without vaccination (Ii1,V
C(t),
i2,V
C(t), Ii3,V
C(t)). Vaccinated individuals of age group i infectedwith
ne of the pneumococcal diseases moved into one of the three
nfectious compartments with vaccination (Ii1,V(t), Ii2,V(t), Ii3,V(t))
with a smaller FOI, (1  pj)(t), where pj represented vaccine effi-
cacy against the jth pneumococcal disease. Infectious individuals
with the jth pneumococcal disease recovered at a rate of ãij and
moved back to the susceptible compartment. Individuals with the
jth pneumococcal disease died from the disease with the case
fatality rate (CFR) j. The dynamic structure is represented in a set
f differential equations as follows:
dSit
dt
N 	i
j ij(t)
i
AiSi(t)
Vi(t)
Ai1Si1(t)
dVit
dt
	iSi(t) j ij(t)1 pj
i

AiVi(t)
Ai1Vi1(t)
dIij,VC(t)
dt
ij(t)Si(t) ij
ij
AiIij,VC(t)
Ai1Iij1,VC(t)
dIij,V(t)
dt
ij(t)1 pjVi(t) ij
ij
AiIij,V(t)
Ai1Iij1,VC(t)
dDij,VC(t)dt
ijIij,VC(t)
hdDij,Vt
dt
ijIij,V(t)
dRit
dt

j
ijIij,VC(t)
 Iij,V(t)iRi(t)AiRi(t)
Ai1Ri1(t)
The initial conditions are described as below; e.g., 60 in I1,V
C(0) is
the prevaccination number of IPD in the first age group (2 years
of age) at time 0 and all other column vectors are similarly defined.
S (0) 393014 414771 4060519 11794340 3972167 2402220′
V(0) 0 0 0 0 0 0′
I1,VC(0) 60 73 57 106 167 291′
I2,VC(0) 19703 9016 9234 12832 6308 52015′
I3,VC(0) 79156 52989 115351 0 0 0′
I1,V(0) 0 0 0 0 0 0′
I2,V(0) 0 0 0 0 0 0′
I3,V(0) 0 0 0 0 0 0′
DV(0) 0 0 0 0 0 0′
DVC(0) 0 0 0 0 0 0′
R(0) 0 0 0 0 0 0′
FOI was estimated by using prevaccination prevalence data [20]. It
can then be expressed as the product of the who-acquire-infec-
tion-from-whom matrix nn [20] and Inx1(t) as follows:
n1(t)nnIn1(t) (1)
where nn contained n
2 parameters, in which âij (1  i, j  n) was
he transmission rate of effective infectious contacts from an in-
ectious person of age group j to a susceptible person of age group i.
evertheless, the number of parameters to be estimated in thewho-
cquire-infection-from-whom matrix would exceed the number of
quations in (1); i.e., it is an identifiability problem. Therefore, an
ssumed structure of contact patterns among different age groups
llowed us to estimate n unknown parameters of the who-acquire-
nfection-from-whom matrix, where n was maximally equal to the
umber of known FOIs in (1) [20]. Because of the complexity of the
ystem, the differential equations were solved numerically.
Model parameters
Demographic data
The age-specific population structure and non-SP–related mortal-
ity were derived from government data [26]. Life-years lost owing
to SP-induced death for individuals in different age groups were
also estimated [26] (see Table 1 in SupplementalMaterials found at
doi:10.1016/j.jval.2011.11.013).
Epidemiological parameters. The average annual disease burden
aused by SP was estimated from 2002 to 2004 by using the Na-
ional Health Insurance Research Database (NHIRD) to reflect pre-
accination disease burden because PCV7 was first introduced in
aiwan in October 2005 (see Table 1 in Supplemental Materials
ound at doi:10.1016/j.jval.2011.11.013). Because IPD was included
s a notifiable disease by the Taiwanese Centers for Disease Con-
rol (CDC) on October 15, 2007, the CFR of microbiologically con-
rmed IPD could be estimated accurately [27]. The CFRs of those
ospitalized with all-cause pneumonia and AOM were derived
g
a
s
p
t
S17V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 5 – S 1 9from theNHIRD. The recovery rate for pneumococcal diseaseswas
derived by using published literature [25].
Vaccine efficacy data
Table 1 in Supplemental Materials found at doi:10.1016/j.jval.
2011.11.013 gives the vaccine efficacy data. Only limited immuno-
enicity data of PCV13 were available. Hence, the direct efficacy
gainst IPD for PCV13 and PCV7 for covered serotypes was as-
umed to be the same (94%) as obtained from the intend-to-treat
opulation in the Northern California Kaiser Permanente pivotal
rial [28]. The overall PCV13 efficacy against IPD (77.5%) was calcu-
lated by multiplying the direct efficacy of PCV7 against IPD (94%)
by a local serotype coverage of PCV13 (82.4%) [29]. The efficacies of
PCV13 against all-cause hospitalized pneumonia and AOM were
assumed to increase proportionally with the serotype coverage
increase of PCV13 for IPD as compared with PCV7 (82.4% vs. 64.7%;
ratio of 1.274) [28]. Therefore, the overall efficacy of PCV13 against
all-cause hospitalized pneumonia (32.4%) was calculated by mul-
tiplying the PCV7 efficacy against hospitalized pneumonia for the
intend-to-treat population (25.5%) with the ratio of serotype in-
crease (1.274) by using World Health Organization–standardized
methodology [30]. Similarly, the overall efficacy of PCV13 against
AOM (8.9%) was calculated by multiplying the PCV7 efficacy
against AOM (7%) estimated in the Finnish Otitis Media vaccine
trial [31,32] with the same ratio. The vaccination-immunity period
was assumed to be 5 years.
Cost parameters
The direct medical cost of treating each pneumococcal disease
was calculated in a payer analysis. The costs included those of
hospitalization, health-care professional consultation, intensive
care unit admissions, medications, and diagnostic tests, esti-
mated from the NHIRD. The average annual cost for each disease
episode was calculated by using data from 2002 through 2004.
A societal analysis included indirect costs, which consisted of
the cost of work lost owing to nonfatal pneumococcal diseases for
the patient, caregiver time, and the cost of work lost owing to
premature pneumococcal death. These two indirect costs were
estimated by using the human capital approach [33]. The expected
cost of work lost owing to pneumococcal death was estimated by
multiplying the life expectancy, derived from the median age of
death for each age group, with the average annual earnings for the
corresponding age group [34].
Cost of vaccination program
As the market price of PCV13 is unavailable in Taiwan, US$91.75
suggested by the US CDCwas used [35]. The cost of vaccine admin-
istration was assumed to be US$4.71 per dose. The breakdown of
the individual costs is presented in Table 2 in Supplemental Ma-
terials found at doi:10.1016/j.jval.2011.11.013.
Vaccine administration
A 90% vaccination coverage of a four-dose vaccination schedule
was assumed for the birth cohort for 182,599 Taiwanese newborns
in 2009 [25]. A three-dose vaccination schedule was also consid-
ered because of recent immunogenicity data [36,37].
Cost-effectiveness analysis
The cost-effectiveness outcome was expressed as the incremental
cost per life-year gained. The CEA was performed from both payer
and societal perspectives with a discount rate of 3% on cost and ef-
fectiveness [34]. Because the cost-effectiveness threshold in Taiwan
is unavailable, the following World Health Organization guidelines
were used [38]: An intervention is “cost-effective” if the incremental
cost-effectiveness ratio (ICER) is less than three times a country’s grossdomestic product (GDP) per capita, and an intervention is “very cost-
effective” if the ICER is less than a country’s GDP per capita [39,40].
Sensitivity analyses
One-way deterministic sensitivity analysis (DSA) andmultivariate
probabilistic sensitivity analysis (PSA) were both performed to
evaluate the sensitivity of outcomes [41]. PSA was conducted to
evaluate the simultaneous impact of parameters [42]. Simulated
outcomes were generated by using the Monte Carlo method. Con-
fidence intervals for ICER and cost-effectiveness acceptability
curves were calculated [43].
Statistical software
Data extraction was conducted by using SAS software (version 9.1,
SAS Institute, Inc., Cary, NC). The systemof differential equations for
the TDMwas solved by using the fourth-order Runge–Kutta method
implemented inMATLAB (R2008a, TheMathWorks, Inc.,Natick,MA).
Results
Base-case model outcomes
Universal infant PCV13 vaccination would help to significantly re-
duce both the clinical burden and the economic burden caused by
SP. As shown in Table 3 in Supplemental Materials found at doi:
10.1016/j.jval.2011.11.013, the vaccination programwas estimated
to prevent 5112 cases of IPD, 535,607 cases of all-cause hospital-
ized pneumonia, 726,986 cases of AOM, and 420 deaths, equivalent
to the loss of 9739 life-years. The estimated annual vaccine cost
was US$62.31 million with a four-dose vaccination schedule. Im-
plementation of the vaccination programwas estimated to lead to
a reduction of 49.3% in direct medical costs (US$252.60 million)
and a reduction of 43.1% in indirect costs of pneumococcal dis-
eases (US$192.31 million).
Cost-effectiveness outcomes
From the payer perspective, a four-dose (three-dose) vaccination
schedule yielded an ICER of US$38,045 (US$22,050) per life-year
gained. From the societal perspective, a four-dose (three-dose) vacci-
nation schedule yielded an ICER of US$18,299 (US$2304). All four ICERs
were less than three times Taiwan’s GDP per capita—US$14,453.
One-way DSA
Under a four-dose vaccination schedule in the societal perspec-
tive, most parameters had a moderate impact on the ICER in the
one-way DSA, causing the ICER to vary within two times Taiwan’s
2009 GDP per capita. Vaccine price had the highest impact, which
varied more than three times the GDP per capita.
Multivariate PSA
Figure 2 in Supplemental Materials found at doi:10.1016/j.jval.
2011.11.013 shows 5000Monte Carlo simulationswith andwithout
the herd effect for the payer and societal perspectives under a
four-dose vaccination schedule as plotted in the cost-effective-
ness plane. Considering direct effects alone, the simulation results
for both perspectives were to the left of the straight line set at a
slope three times the GDP (shown in blue and dark blue). Including
the herd effect, the simulation results for both perspectives were
located between the straight lines set at one and three times the
GDP per capita (shown in pink and brown). The 95% confidence
interval of the ICER was US$10,186 to US$34,563). Figure 3 in Sup-
plemental Materials found at doi:10.1016/j.jval.2011.11.013 shows
the cost-effectiveness acceptability curve generated under a four-
dose vaccination schedule for both perspectives. Given a maxi-
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S18 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 5 – S 1 9mum cost-effectiveness threshold of three times the GDP per cap-
ita, the probability of being cost-effective from the societal
perspective reached 100% at a cost-effectiveness threshold of
US$37,634, which was below the threshold of three times the GDP
per capita. From the payer perspective, the threshold for reaching
100% cost-effectiveness was US$57,311, well beyond three times
the GDP per capita.
Discussion
Our results suggested that universal infant PCV13 vaccination in
Taiwan would substantially reduce the morbidity, mortality, and
disease costs of SP infection. Previous economic evaluations of
CV in Asian countries were based on static models, and the CEA
f PCV has not been conducted in Taiwan despite the growing
wareness of the economic burden of pneumococcal diseases. To
he best of our knowledge, our studywas the first CEA of the PCV13
accination program using a TDM in Asia.
A major strength of our study was that the TDM can capture
he herd effect, which greatly influences the ICER, as demon-
trated by other studies [44-47]. Another strength of our studywas
hat epidemiological and cost data were derived from the NHIRD,
hich contains 99% of the Taiwanese patient data [48]. Therefore,
revaccination data were reliable and could represent accurate
isease burden in Taiwan.
The CFR calculated by using the NHIRD death code before hos-
ital discharge was probably underestimated because deaths that
ccurred outside hospitals were excluded. To circumvent this,
aiwanese CDC database was used to obtain accurate CFR of mi-
robiologically confirmed IPD. As the CDC database does not con-
ain data on all-cause hospitalized pneumonia, more precise esti-
ates of pneumonia CFR could not be obtained. Although partial
nformation was available, the impact on cost-effectiveness re-
ults was only moderate in one-way DSA.
As expected, one-wayDSA indicated that the resultsweremost
ensitive to the vaccine price: a 50% reduction in price from the
ase-case valuewouldmake the vaccination program cost-saving,
hile a 50% increase in price would generate an unfavorable ICER
f US$48,800, which exceeded three times the GDP per capita. Other
nfluential parameterswere the recovery rate, the incidence of pneu-
onia, and the vaccine-immunity period, because the recovery rate
nd the incidence of pneumonia also had a considerable impact on
he ICER. It is vital to further study the epidemiology of pneumococ-
al diseases in Taiwan. As the true protection period for vaccine is
ot totally clear, shortening the vaccine immunity period to 2.5 years
ncreased the ICER toUS$36,011 andassuming a 10-year vaccinepro-
ection reduced the ICER to US$12,399.
It is important to note that the TDM itself is nonstochastic, with
utcomes fully determined by initial conditions. Multivariate PSA
ade cost-effectiveness results stochastic to aid inferential deci-
ion making. As shown in Figure 2 in Supplemental Materials
ound at doi:10.1016/j.jval.2011.11.013, the herd effect was amajor
river of observed cost-effectiveness with PCV13 vaccination in
oth perspectives. The removal of this effect would produce an
nfavorable ICER. Another important determinant was the indi-
ect cost. Figure 3 in Supplemental Materials found at doi:10.1016/
.jval.2011.11.013 shows that in the payer perspective the vaccina-
ion program would have a probability of only 52% of being cost-
ffectivewith three times the GDP thresholdwhile the inclusion of
aved indirect cost would make the vaccination program 100%
ost-effective with the same threshold.
In multivariate PSA, direct disease treatment costs were as-
umed to follow a lognormal distribution,whichwas in agreement
ith the distribution of cost in the NHIRD. With the absence of
CV13 vaccine efficacy data, the distribution of vaccine efficacies
as assumed to follow triangular distributions because informa-
ion on these distributions was limited [49]. Furthermore, otheristributions of vaccine efficacy, such as beta and uniform distri-
utions, were also considered in our secondary analyses, and the
esults were very similar.
There are a few limitations in our study. First, we did not con-
ider the possible increase in nasopharyngeal carriage of nonvac-
ine serotypes, a well-observed consequence of serotype replace-
ent in several countries that routinely used PCV7 [50,51]. The
iterature indicates an emergence of serotype 19A in Taiwan even
ith a low coverage of PCV7 (i.e., 15.9% of coverage with PCV7
mong population younger than 5 years) [29]. Hence, the overall
linical benefits might have been overestimated. Second, a reduc-
ion in the incidenceofantibiotic–non-susceptible IPDwasattributed
o large-scale PCV7 vaccination [52]. This potential additional benefit
ashard toquantify andhencewasnot included in this study.Third,
he relationship between the duration of nasopharyngeal carriage
nd the onset of pneumococcal diseases was not explored. Future
fforts are needed to build a more comprehensive TDM.
Our CEA is conservative. First, the study used only life-year
utcome owing to the absence of local quality-of-life data. Second,
he four complications associated with meningitis, that is, deaf-
ess, brain damage, focal neurological deficit, and chronic sei-
ures, were included in previous pharmacoeconomic studies of
CV [15,53] but not in the present analysis owing to lack of data.
urther research would be directed on the use of the TDM to de-
ign optimal vaccination strategies against pneumococcal dis-
ases with limited vaccine resources [54].
Conclusions
The TDM that can account for the herd effect was used to evaluate
the cost-effectiveness of universal infant PCV13 vaccination. Our
results demonstrated that PCV13 vaccination would be cost-effec-
tive in Taiwan from both the payer and societal perspectives. CEA
using the TDM can provide more information to decision makers
for assessing the long-term cost-effectiveness of a large-scale vac-
cination program.
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